that describes a single glioblastoma patient with a progression-free survival of 69 months following treatment with a personalized DCV combined with depletion of Treg cells, ICI with anti-PD-1, and an immune adjuvant Poly I:C (157). The gene discussed is PDCD1; the disease is glioblastoma.